Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) has been given an average recommendation of "Moderate Buy" by the twenty-six research firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-one have assigned a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $319.17.

ALNY has been the subject of a number of recent analyst reports. Scotiabank upped their price objective on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a report on Monday, March 31st. Wells Fargo & Company upped their price target on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an "equal weight" rating in a research note on Friday, March 21st. William Blair reissued an "outperform" rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Citigroup upped their target price on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a research note on Friday, March 21st. Finally, UBS Group increased their target price on shares of Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the stock a "buy" rating in a report on Friday, May 2nd.

Insider Activity at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 19,297 shares of the firm's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total value of $5,904,882.00. Following the completion of the transaction, the chief executive officer now directly owns 48,948 shares of the company's stock, valued at approximately $14,978,088. This trade represents a 28.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Jennison Associates LLC bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $61,160,000. Strategic Financial Concepts LLC bought a new position in Alnylam Pharmaceuticals during the fourth quarter worth $41,529,000. Truist Financial Corp boosted its position in Alnylam Pharmaceuticals by 136.6% during the fourth quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company's stock worth $1,035,000 after purchasing an additional 2,539 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its position in Alnylam Pharmaceuticals by 3.0% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company's stock worth $67,464,000 after purchasing an additional 8,462 shares during the period. Finally, Ieq Capital LLC boosted its position in Alnylam Pharmaceuticals by 825.5% during the fourth quarter. Ieq Capital LLC now owns 38,806 shares of the biopharmaceutical company's stock worth $9,131,000 after purchasing an additional 34,613 shares during the period. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock traded up $2.69 during trading hours on Wednesday, hitting $308.00. 761,194 shares of the company's stock were exchanged, compared to its average volume of 929,505. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The stock has a market cap of $40.16 billion, a price-to-earnings ratio of -141.93 and a beta of 0.17. Alnylam Pharmaceuticals has a 52 week low of $147.25 and a 52 week high of $310.23. The stock's 50-day moving average is $262.51 and its 200-day moving average is $256.16.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The company had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. Alnylam Pharmaceuticals's quarterly revenue was up 20.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.16) earnings per share. As a group, research analysts forecast that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.